Prader-Willi Syndrome
Characteristic facial features: narrow forehead, almond-shaped eyes
Also Known As	Prader-Willi-Labhart Syndrome, PWS
ICD-10	Q87.1
OMIM	176270
Inheritance	Autosomal dominant (imprinted); usually sporadic
Gene Region	15q11.2-q13 (paternal allele)
Chromosome	15q11.2
Onset	Infancy (hypotonia); childhood (hyperphagia)
Key Features	Infantile hypotonia, hyperphagia, obesity, intellectual disability, behavioral problems
Prevalence	1 in 10,000-30,000
Treatment	Growth hormone, strict diet control, behavioral therapy

Prader-Willi Syndrome

Introduction

Prader Willi Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Prader-Willi Syndrome (PWS) is a rare genetic disorder caused by loss of function of genes on the paternal chromosome 15q11.2-q13 region ^{1Dampened surge in heart rate at respiratory event termination in children with Prader-Willi syndromePMID 41691910Open reference}. The condition is characterized by a distinctive two-phase clinical presentation: infants present with severe hypotonia and feeding difficulties, while childhood onset brings hyperphagia (uncontrollable hunger) leading to severe obesity if not strictly managed ^{2Unravelling Narcolepsy: A Series of Complex Pediatric CasesPMID 41669756Open reference}.

First described by Swiss doctors Andrea Prader, Alexis Labhart, and Heinrich Willi in 1956, Prader-Willi syndrome affects approximately 1 in 10,000 to 1 in 30,000 individuals worldwide. The syndrome represents the most common known genetic cause of life-threatening obesity ^{1Dampened surge in heart rate at respiratory event termination in children with Prader-Willi syndromePMID 41691910Open reference}.

Genetics and Pathophysiology

Genomic Imprinting

Prader-Willi syndrome provides another critical example of genomic imprinting in humans. The 15q11-q13 region contains multiple imprinted genes that are expressed in a parent-of-origin-specific manner:

• Paternal-expressed genes: MKRN3, MAGEL2, NDN, SNORD116 (SNURF-SNRPN), and others

• Maternal-expressed genes: Only OCA2 is maternally expressed in this region

Loss of the paternal allele results in Prader-Willi syndrome, while loss of the maternal allele causes Angelman syndrome (a related but distinct disorder) ^{3Functional Independence in Adults With Prader-Willi Syndrome: First Report Using the FIM InstrumentPMID 41368943Open reference}.

Genetic Mechanisms

Mechanism	Frequency	Description
Paternal 15q11-q13 deletion	~70%	Microdeletion on paternal chromosome
Maternal uniparental disomy	~25%	Two maternal copies of chromosome 15
Imprinting center defect	~3-5%	Epigenetic silencing of paternal alleles
Translocation	<1%	Rare chromosomal rearrangements

The SNORD116 cluster of small nucleolar RNAs (snoRNAs) appears particularly important in driving the PWS phenotype, especially the hyperphagia and behavioral characteristics ^{4Circulating levels of ghrelin and hyperphagia in patients with rare genetic neurodevelopmental disordersPMID 41811759Open reference}.

Key Genes and Their Functions

• SNORD116 (HBII-85): Loss of this snoRNA cluster is strongly associated with hyperphagia and PWS phenotype

• MKRN3: Encodes makorin ring finger protein 3, involved in pubertal timing

• MAGEL2: Involved in circadian rhythm regulation and hypothalamic function

• NDN (Necdin): Neuronal differentiation and survival

• OCA2: Pigmentation; loss correlates with fair skin and light hair

Clinical Features

Phase 1: Infancy (Birth to ~2 years)

Neonatal Period

• Severe hypotonia (floppy infant syndrome)

• Poor sucking reflex and feeding difficulties

• Failure to thrive

• Delayed motor milestones

• Distinctive facial features: almond-shaped eyes, narrow forehead, triangular mouth

• Cryptorchidism (undescended testicles) in males

• Weak cry and decreased activity

Characteristic Facial Features

• Narrow bifrontal diameter

• Almond-shaped palpebral fissures

• Downturned triangular mouth

• Full cheeks (in infancy)

• Fair skin and light hair (compared to family)

Phase 2: Childhood (2 years onward)

Hyperphagia and Obesity

• Onset typically between 2-6 years

• Food-seeking behavior and obsession with food

• Lack of satiety sensation

• Chronic overeating leading to rapid weight gain

• Food-related behavioral problems

• Risk of life-threatening obesity if not controlled

• Compulsive eating and food foraging

Neurocognitive Profile

• Mild to moderate intellectual disability (IQ ~60-80)

• Learning disabilities and cognitive challenges

• Language development delays

• Strengths in visual spatial abilities

• Executive function deficits

Behavioral Manifestations

• Temper outbursts and tantrums

• Stubbornness and oppositional behavior

• Compulsive behaviors (skin picking, hair pulling)

• Attention deficits

• Anxiety and mood instability

• Sleep disorders

• Psychiatric manifestations in adulthood

Phase 3: Adulthood

• Continued hyperphagia (may improve with age)

• Obesity-related complications (diabetes, cardiovascular disease)

• Behavioral issues may improve but persist

• Social and vocational challenges

• Hypogonadism and infertility

• Scoliosis risk

• Osteoporosis risk

Diagnosis

Clinical Criteria

The clinical diagnosis involves recognition of the characteristic phenotype:

• History of infantile hypotonia with poor feeding

• Development of hyperphagia and food obsession

• Characteristic facial features

• Developmental delays and learning disabilities

Genetic Testing

Confirmation requires genetic testing:

1. DNA methylation analysis: Detects absence of paternal-specific methylation pattern (~99% sensitive)

2. Chromosomal microarray (CMA): Identifies 15q11-q13 deletion (~70% of cases)

3. SNP array: Detects maternal uniparental disomy (~25%)

4. FISH: Can detect deletions

5. ** methylation-specific MLPA**: Detects deletions and UPD

Differential Diagnosis

• Other causes of childhood obesity

• Angelman syndrome (related imprinting disorder)

• Bardet-Biedl syndrome

• Leptin deficiency

• Hypothalamic tumors

• Other intellectual disability syndromes

Management and Treatment

Multidisciplinary Approach

Management requires a team approach including:

• Endocrinologist

• Geneticist

• Dietitian

• Behavioral specialist

• Occupational/physical therapist

• Speech therapist

• Psychiatrist/psychologist

Key Management Strategies

Dietary Management

• Strict food portion control

• Environmental food security (locked kitchens, restricted access)

• Low-calorie diet

• Regular weight monitoring

• Family education and behavioral interventions

• Vitamin and mineral supplementation

Growth Hormone Therapy

• Improves linear growth

• Increases lean body mass

• Improves motor function

• May improve cognitive development

• Must be carefully monitored

• Requires genetic confirmation before initiating

Behavioral Interventions

• Structured routines

• Cognitive behavioral therapy

• Social skills training

• Anger management

• Reward systems for appropriate behavior

• Addressing compulsions (skin picking)

Medical Management

• Treatment of obesity complications

• Sleep studies (sleep apnea common)

• Orthopedic monitoring (scoliosis)

• Hormone replacement therapy (hypogonadism)

• Psychiatric medications as needed

Emerging Therapies

• Setmelanotide (MC4R agonist): FDA-approved for rare genetic obesity disorders; being studied in PWS

• Targeted genetic therapies under development

• Hypothalamic dysfunction modulation approaches

Relationship to Neurodegenerative Diseases

While primarily a neurodevelopmental disorder, Prader-Willi syndrome shares interesting features with neurodegenerative conditions:

Shared Pathways

1. Hypothalamic dysfunction: Both PWS and various neurodegenerative diseases involve hypothalamic dysfunction

2. Sleep disorders: High prevalence of sleep disturbances parallels findings in neurodegeneration

3. Mitochondrial dysfunction: Emerging evidence suggests mitochondrial abnormalities in PWS

4. Inflammatory processes: Some evidence of systemic inflammation in PWS

Research Implications

Studying PWS provides insights into:

• Hypothalamic regulation of appetite and satiety

• Genomic imprinting mechanisms

• Genetic causes of obesity

• Neurodevelopmental disorders with behavioral components

Animal Models

Mouse models with paternal 15q11-q13 deletions recapitulate key features:

• Neonatal lethality with paternal deficiency

• Growth retardation

• Behavioral abnormalities

• Metabolic dysregulation

Prognosis

With early diagnosis and comprehensive management:

• Life expectancy can be normal with appropriate care

• Quality of life significantly improved with behavioral and medical management

• Adult independence varies (some achieve semi-independence)

• Obesity-related complications are the major cause of morbidity

• Behavioral issues require ongoing support throughout life

See Also

• Angelman Syndrome — Related imprinting disorder (15q11-q13)

• Rett Syndrome — Related neurodevelopmental disorder

• Hypothalamic Dysfunction — Key to appetite regulation

• Obesity — Major comorbidity

External Links

• GeneReviews: Prader-Willi Syndrome

• NORD: Prader-Willi Syndrome

• Prader-Willi Syndrome Association (USA)

• Clinical Trials for Prader-Willi Syndrome

• OMIM: Prader-Willi Syndrome

• PubMed: Prader-Willi Syndrome

Background

The study of Prader Willi Syndrome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• Dampened surge in heart rate at respiratory event termination in children with Prader-Willi syndrome. (2026 May) - Sleep medicine

• Unravelling Narcolepsy: A Series of Complex Pediatric Cases. (2026 Apr) - Neurology. Clinical practice

• Functional Independence in Adults With Prader-Willi Syndrome: First Report Using the FIM Instrument. (2026 Apr) - American journal of medical genetics. Part A

• Circulating levels of ghrelin and hyperphagia in patients with rare genetic neurodevelopmental disorders. (2026 Mar 11) - The Journal of clinical endocrinology and metabolism

• Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. (2026 Mar) - Obesity (Silver Spring, Md.)